DNMT3A Gene Acute Myeloid Leukemia Somatic DNMT3A Related Genetic Test
At DNA Labs UAE, we offer the DNMT3A Gene Acute Myeloid Leukemia Somatic DNMT3A Related Genetic Test at a cost of AED 3000.0.
Test Components
- Price: 3000.0 AED
- Sample Condition: Blood or Extracted DNA or One drop Blood on FTA Card
- Report Delivery: 3 to 4 Weeks
- Method: NGS Technology
- Test Type: Cancer
- Doctor: Oncologist
- Test Department: Genetics
Pre Test Information
Before undergoing the DNMT3A Gene Acute Myeloid Leukemia Somatic DNMT3A Related Genetic Test, it is important to provide the clinical history of the patient. Additionally, a genetic counseling session will be conducted to draw a pedigree chart of family members affected by DNMT3A Gene Acute Myeloid Leukemia Somatic DNMT3A Related Genetic Test gene DNMT3A.
Test Details
The DNMT3A gene is responsible for producing an enzyme called DNA methyltransferase 3 alpha (DNMT3A), which is involved in DNA methylation and gene activity regulation. Acute myeloid leukemia (AML) is a type of cancer that affects the blood and bone marrow. Some cases of AML are caused by genetic mutations, including mutations in the DNMT3A gene. These mutations are somatic, meaning they occur in the body’s cells and are not inherited.
NGS (Next-Generation Sequencing) is a genetic testing method that can analyze multiple genes simultaneously. In the context of DNMT3A-related AML, NGS genetic testing is used to identify mutations in the DNMT3A gene and other relevant genes associated with the development and progression of AML.
The DNMT3A-related NGS genetic test involves obtaining a sample, usually through a blood draw, and analyzing the DNA within the sample to identify any mutations or changes in the DNMT3A gene. This information aids in the diagnosis of AML and determining appropriate treatment options.
It is important to note that the presence of a DNMT3A mutation does not guarantee the development of AML, as other factors contribute to the disease. Additionally, not all cases of AML will have DNMT3A mutations. If you have specific concerns or questions about the DNMT3A gene, AML, or genetic testing, it is recommended to consult with a healthcare professional or a genetic counselor for personalized information and guidance based on your individual situation.
Test Name | DNMT3A Gene Acute myeloid leukemia somatic DNMT3A related Genetic Test |
---|---|
Components | |
Price | 3000.0 AED |
Sample Condition | Blood or Extracted DNA or One drop Blood on FTA Card |
Report Delivery | 3 to 4 Weeks |
Method | NGS Technology |
Test type | Cancer |
Doctor | Oncologist |
Test Department: | Genetics |
Pre Test Information | Clinical History of Patient who is going for DNMT3A Gene Acute myeloid leukemia, somatic, DNMT3A related NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with DNMT3A Gene Acute myeloid leukemia, somatic, DNMT3A related NGS Genetic DNA Test gene DNMT3A |
Test Details |
The DNMT3A gene is a gene that provides instructions for making an enzyme called DNA methyltransferase 3 alpha (DNMT3A). This enzyme is involved in a process called DNA methylation, which helps regulate gene activity. Acute myeloid leukemia (AML) is a type of cancer that affects the blood and bone marrow. In some cases of AML, there can be specific genetic mutations, including mutations in the DNMT3A gene. These mutations are somatic mutations, meaning they occur in the cells of the body other than the reproductive cells and are not inherited. NGS (Next-Generation Sequencing) is a type of genetic testing that can analyze multiple genes simultaneously. In the context of DNMT3A-related AML, NGS genetic testing can be used to identify mutations in the DNMT3A gene and other relevant genes that may be associated with the development and progression of AML. The DNMT3A-related NGS genetic test involves obtaining a sample, usually through a blood draw, and analyzing the DNA within the sample to identify any mutations or changes in the DNMT3A gene. This information can help in diagnosing AML and determining appropriate treatment options. It is important to note that the presence of a DNMT3A mutation does not necessarily mean a person will develop AML, as there are other factors involved in the development of the disease. Additionally, not all cases of AML will have DNMT3A mutations. If you have specific concerns or questions about the DNMT3A gene, AML, or genetic testing, it is recommended to consult with a healthcare professional or a genetic counselor who can provide personalized information and guidance based on your individual situation. |